Clinical trials: Community Pneumonia
Tracheitis, Tracheobronchitis
Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR
This post-marketing observational study (PMOS) will be conducted in a prospective, single-arm, single-country, multicenter format.
- Conditions
- Tracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis
- Trial name
- NCT01130883
- Where
- 135 sites in Czechia
- Volunteers
- 3,130 people
- Sponsor
- Abbott
Pneumonia, Bacterial
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to Streptococcus pneumoniae.
- Trial name
- NCT00538694
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Pneumonia
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of…
- Trial name
- NCT01561794
- Testing
- Ciprofloxacin (Cipro, BAYQ3939)
- Where
- 20 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Bayer
Bacterial Pneumonia, Community-Acquired Infections
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT02531438
- Testing
- Omadacycline, Moxifloxacin
- Where
- 140 sites in United States, Belgium and 23 more
- Volunteers
- 774 people
- Sponsor
- Paratek Pharmaceuticals Inc
Community-acquired Pneumonia
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
- Trial name
- NCT04160260
- Testing
- Omadacycline
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Paratek Pharmaceuticals Inc
Infections, Bacterial
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in…
- Trial name
- NCT05340257
- Testing
- Augmentin ES
- Where
- 2 sites in Brazil
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit).
- Trial name
- NCT05962606
- Testing
- AON-D21
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 150 people
- Sponsor
- Aptarion Biotech AG
Infections, Community Acquired Pneumonia
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
This is a study of safety and effectiveness of ceftaroline fosamil in children with Community Acquired Bacterial Pneumonia receiving antibiotic therapy in the hospital.
- Trial name
- NCT01530763
- Testing
- Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 161 people
- Sponsor
- Forest Laboratories
Community-acquired Pneumonia
Oral Nemonoxacin in Treating Elderly Patients With CAP
This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).
- Trial name
- NCT05133752
- Testing
- Nemonoxacin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Community Acquired Pneumonia
Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
In order to verify the clinical value and safety of Xiyanping injection in children with CAP, we intend to carry out this multi-center, large-sample, non-intervention clinical research through more rigorous and scientific design.
- Trial name
- NCT04158310
- Volunteers
- 9,207 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Pneumonia
Zithromax EV in Community-Acquired Pneumonia (CAP)
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP.
- Trial name
- NCT00137007
- Testing
- Azithromycin, Ampicillin/sulbactam
- Volunteers
- 151 people
- Sponsor
- Pfizer
Pneumonia
CAPRIVI: Community Acquired Pneumonia: Treatment With Avelox® in Hospitalized Patients
The aim of this study is to obtain data from hospitalized Community Acquired Pneumonia (CAP) patients on the disease including disease severity, clinical signs and symptoms and measures used for diagnosis in daily routine…
- Trial name
- NCT00987792
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 11 sites in Croatia, France and 9 more
- Volunteers
- 2,595 people
- Sponsor
- Bayer
Pneumonia
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with…
- Trial name
- NCT00665327
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Levofloxacin
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 401 people
- Sponsor
- Bayer
Community-Acquired Pneumonia (CAP)
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
The purpose of this study is to determine whether RX-1741, an oxazolidinone antibiotic, is safe and effective in the treatment of mild to moderate community acquired pneumonia (CAP).
- Trial name
- NCT00640926
- Testing
- Radezolid
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 158 people
- Sponsor
- Melinta Therapeutics, Inc.
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Respiratory Tract Infections, Chronic Bronchitis
KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections
The purpose of this study is to determine if 1 course of antibiotic treatment with telithromycin is superior to azithromycin in the treatment of lower respiratory tract infections (LRTIs), acute exacerbations of chronic…
- Conditions
- Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
- Trial name
- KEYS (NCT00132951)
- Testing
- Telithromycin, Azithromycin
- Where
- 2 sites in United States, Canada
- Volunteers
- 2,051 people
- Sponsor
- Sanofi
Infectious Pneumonia, Severe COVID-19
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Primary objective: To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
- Trial name
- NCT05254990
- Testing
- Reparixin
- Where
- 74 sites in United States, Argentina and 5 more
- Volunteers
- 414 people
- Sponsor
- Dompé Farmaceutici S.p.A
Covid19, Community-Acquired Respiratory Tract Infection
Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19
Solving the problem of detecting asymptomatic carriers who can transmit infection is key to protecting vulnerable residents of nursing homes and assisted living facilities, to protecting frontline workers who care for them, and…
- Trial name
- NCT04548895
- Testing
- Observational measurement of biometric data. No change to health care provided.
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Health Stream Analytics, LLC
Pneumonia, Sepsis
A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
- Trial name
- NCT00042588
- Testing
- Recombinant Chimeric Monoclonal Antibody
- Where
- United States
- Sponsor
- ICOS Corporation
Infections, Streptococcal
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
This is a study in a large number of healthy children less than 3 years old to measure the efficacy of GlaxoSmithKline (GSK) Biologicals' 10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A) to…
- Trial name
- NCT00466947
- Testing
- Pneumococcal conjugate vaccine GSK1024850A, Havrix, Engerix-B
- Where
- 22 sites in Argentina, Colombia and 1 more
- Volunteers
- 23,802 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline